SBC Medical Group Holdings Incorporated (SBC)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 41/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.63% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- SBC Medical to Present at Cantor Fitzgerald Hong Kong’s Inaugural Asia Longevity Forum
- SBC Medical to Participate in Several Upcoming Investor Conferences in October 2026
- SBC Medical Group Re-Accelerates Growth as EBITDA Surges 32% in Q2
- SBC Medical Group Holdings Inc (SBC) (Q2 2026) Earnings Call Highlights: Profit Growth Outpaces ...
- SBC Medical (SBC) Q2 2026 Earnings Call Transcript
- SBC Medical Group Q2 Growth Re-Accelerates as EBITDA Surges 32%
- Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream
- SBC Medical to Announce 2Q 2026 Financial Results
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for SBC Medical Group Holdings Incorporated.
Full SBC Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.